Moreover, combining anti‐MSLN antibody with personalized neoantigen vaccine could significantly enhance the immunotherapy efficacy of pancreatic cancer by reducing apCAF cells to interrupt the conversion of naive CD4+ T cells to Tregs, and therefore increasing the infiltration of tumor‐specific T cells. Here, CD4 is linked to pancreatic neoplasm.